Virtual Reality App shown to reduce common phobias through clinical trial in New Zealand

SECTOR UPDATE - oVRcome

Results from a New Zealand University trial suggest fresh hope for the estimated one-in-twelve people worldwide suffering from a fear of flying, needles, heights, spiders and dogs.

The trial, led by Associate Professor Cameron Lacey, from the Department of Psychological Medicine, at the University of Otago, studied phobia patients using a headset and a smartphone app treatment programme – a combination of Virtual Reality (VR) 360-degree video exposure therapy and cognitive behavioral therapy (CBT).

Participants downloaded a fully self-guided smartphone app called “oVRcome”, developed by New Zealand based tech entrepreneur Adam Hutchinson, aimed at treating patients with phobia and anxiety.

The app, paired with a VR headset, immerses participants in virtual environments so as to relax and distract technology to help people overcome anxiety disorders and social anxiety through VR exposure therapy. Anxiety and phobias include heights, spiders, flying, dogs and dogs

The results from the trial, just published in the Australian and New Zealand Journal of Psychiatry, https://journals.sagepub.com/doi/full/10.1177/00048674221110779 showed a 75 per cent reduction in phobia symptoms after six weeks of the treatment programme.

“The improvements they reported suggests there’s great potential for the use of VR and mobile phone apps as a means of self-guided treatment for people struggling with often-crippling phobias,” Associate Professor Lacey says.

“Participants demonstrated a strong acceptability of the app, highlighting its potential for delivering easily accessible, cost-effective treatment at scale, of particular use for those unable to access in-person exposure therapy to treat their phobias.”

Adam was inspired to develop oVRcome after becoming increasingly alarmed by mental health statistics. Recognising that accessibility was a key issue, he began working with a team of clinical psychologists to develop an accessible smart-phone based tool to help. It is estimated that up to 80% of anxiety sufferers do not seek treatment currently. Barriers include cost, location of the patient, the stigma of going to a psychologist and the lack of trained psychologists.

A total of 129 people took part in the six-week randomized, controlled trial, between May 2021 and December 2021, with a 12-week follow-up. Participants needed to be aged between 18-64 years, have a fear of either flying, heights, needles, spiders and dogs. They were emailed weekly questionnaires to record their progress. Those experiencing adverse events could request contact from a clinical psychologist at any stage.

Participants experiencing all five types of phobia showed comparable improvements in the Severity Measures for Specific Phobia scale over the course of the trial. There were no participant withdrawals due to intervention-related adverse events.

“The oVRcome app involves what’s called “exposure therapy, a form of CBT exposing participants to their specific phobias in short bursts, to build up their tolerance to the phobia in a clinically-approved and controlled way,” Associate Professor Lacey says.

“Some participants reported significant progress in overcoming their phobias after the trial period, with one feeling confident enough to now book an overseas family holiday, another lining up for a Covid vaccine and another reporting they now felt confident not only knowing there was a spider in the house but that they could possibly remove it themselves.”

The app programme consisted of standard CBT components including psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention model. Participants were able to select their own exposure levels to their particular phobia from a large library of VR videos.

“This means the levels of exposure therapy could be tailored to an individual’s needs which is a particular strength. The more traditional in-person exposure treatment for specific phobias have a notoriously high dropout rate due to discomfort, inconvenience and a lack of motivation in people seeking out fears to expose themselves to. With this VR app treatment, trialists had increased control in exposure to their fears, as well as control over when and where exposure occurs,” says Associate Professor Lacey.

Says Adam, “The trial has allowed us to explore efficacy and benefit from robust learnings. We’re really pleased to learn that users were able to build confidence and take steps toward conquering their phobias. While there has been large growth in the number of apps treating anxiety and mental health issues, only a few have been rigorously clinically studied. The findings from the trial give us real confidence as we launch the product internationally. We know that we can make a difference for so many.”

Anyone suffering from phobia or anxiety, including social anxiety is invited to find out more at www.oVRcome.io.

Source: oVRcome media release

Sector updates are provided by organisations to eHealthNews.nz and have not necessarily been edited or checked for accuracy. Any queries should be directed to the organisation issuing the release.

Do you have an item to add to sector updates?

Email your information to us at updates@hinz.org.nz

Return to eHealthNews.nz home page